Last update 29 Aug 2025

Zeprumetostat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
EBI 2554, SHR 2554, SHR2554
+ [1]
Target
Action
inhibitors
Mechanism
EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors), Epigenetic drug
Inactive Organization-
Drug Highest PhaseApproved
RegulationPriority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H44N4O4
InChIKeyYLZVNQZYAYVUCW-UHFFFAOYSA-N
CAS Registry2098545-98-1

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Peripheral T-cell lymphoma unspecified recurrent
China
29 Aug 2025
Peripheral T-cell lymphoma unspecified refractory
China
29 Aug 2025
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Peripheral T-Cell LymphomaPhase 3
China
17 Jan 2024
Gastroesophageal junction adenocarcinomaPhase 2
China
01 Sep 2025
Metastatic Gastric CarcinomaPhase 2
China
01 Sep 2025
stomach adenocarcinomaPhase 2
China
01 Sep 2025
Advanced gastric carcinomaPhase 2
China
22 Aug 2025
Gastrooesophageal junction cancerPhase 2
China
22 Aug 2025
Advanced Prostate CarcinomaPhase 2
China
06 Sep 2024
Follicular LymphomaPhase 2
China
01 Apr 2024
Refractory Follicular LymphomaPhase 2
China
01 Apr 2024
Refractory Classic Hodgkin LymphomaPhase 2
China
14 Jun 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
67
kpujwvhhns(jsdafcewip) = evidbrothk uudyvovsya (jcrpbcebsm, 51.5 - 75.5)
Met
Positive
12 Jun 2025
Phase 1
28
yaircdvcze(bjyfysfrqb) = gqdpkvtxoz hyxpxioibl (ohhbhumimr, 41 - 78)
Positive
01 Apr 2024
Phase 1
32
mwfwjuicrt(jirlkxmjym) = SHR2554 350mg bid plus SHR-1701 30mg/kg q3w ecytkkwusm (spbjxjslbc )
Positive
31 May 2023
Phase 1
113
exkdnvypjw(dxhfwfoypv) = ryhutmqmli omsdnkkobg (vujmubjlmu )
Positive
01 Jul 2022
Phase 1
113
dywzuzxokq(luorokggae) = berxcdjcxy nteuhydqhg (hpebafhrog, 42.1 - 73.7)
-
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free